mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma
- PMID: 22677901
- PMCID: PMC3389427
- DOI: 10.1038/bjc.2012.239
mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma
Abstract
Background: Degradation of the extracellular matrix is fundamental to tumour development, invasion and metastasis. Several protease families have been implicated in the development of a broad range of tumour types, including oesophago-gastric (OG) adenocarcinoma. The aim of this study was to analyse the expression levels of all core members of the cancer degradome in OG adenocarcinoma and to investigate the relationship between expression levels and tumour/patient variables associated with poor prognosis.
Methods: Comprehensive expression profiling of the protease families (matrix metalloproteinases (MMPs), members of the ADAM metalloproteinase-disintegrin family (ADAMs)), their inhibitors (tissue inhibitors of metalloproteinase), and molecules involved in the c-Met signalling pathway, was performed using quantitative real-time reverse transcription polymerase chain reaction in a cohort of matched malignant and benign peri-tumoural OG tissue (n=25 patients). Data were analysed with respect to clinico-pathological variables (tumour stage and grade, age, sex and pre-operative plasma C-reactive protein level).
Results: Gene expression of MMP1, 3, 7, 9, 10, 11, 12, 16 and 24 was upregulated by factors >4-fold in OG adenocarcinoma samples compared with matched benign tissue (P<0.01). Expression of ADAM8 and ADAM15 correlated significantly with tumour stage (P=0.048 and P=0.044), and ADAM12 expression correlated with tumour grade (P=0.011).
Conclusion: This study represents the first comprehensive quantitative analysis of the expression of proteases and their inhibitors in human OG adenocarcinoma. These findings implicate elevated ADAM8, 12 and 15 mRNA expression as potential prognostic molecular markers.
Figures


Similar articles
-
Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma.J Surg Oncol. 2011 Mar 1;103(3):243-7. doi: 10.1002/jso.21824. Epub 2010 Dec 22. J Surg Oncol. 2011. PMID: 21337552
-
Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.Clin Cancer Res. 2010 Apr 1;16(7):2022-35. doi: 10.1158/1078-0432.CCR-09-2525. Epub 2010 Mar 21. Clin Cancer Res. 2010. PMID: 20305301
-
Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.Clin Transl Oncol. 2017 Jan;19(1):58-66. doi: 10.1007/s12094-016-1503-3. Epub 2016 Mar 30. Clin Transl Oncol. 2017. PMID: 27026568 Clinical Trial.
-
Differential expressions of matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs and their endogenous inhibitors among histologic subtypes of lung cancers.Anticancer Agents Med Chem. 2012 Sep;12(7):744-52. doi: 10.2174/187152012802650156. Anticancer Agents Med Chem. 2012. PMID: 22292754 Review.
-
Introduction: MMPs, ADAMs/ADAMTSs research products to achieve big dream.Anticancer Agents Med Chem. 2012 Sep;12(7):688-706. doi: 10.2174/187152012802650200. Anticancer Agents Med Chem. 2012. PMID: 22292751 Review.
Cited by
-
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.EMBO Mol Med. 2014 Feb;6(2):278-94. doi: 10.1002/emmm.201303373. Epub 2013 Dec 27. EMBO Mol Med. 2014. PMID: 24375628 Free PMC article.
-
Plasma matrix metalloproteinase 1 improves the detection and survival prediction of esophageal squamous cell carcinoma.Sci Rep. 2016 Jul 20;6:30057. doi: 10.1038/srep30057. Sci Rep. 2016. PMID: 27436512 Free PMC article.
-
Membrane-Type 5 Matrix Metalloproteinase (MT5-MMP): Background and Proposed Roles in Normal Physiology and Disease.Biomolecules. 2025 Aug 3;15(8):1114. doi: 10.3390/biom15081114. Biomolecules. 2025. PMID: 40867559 Free PMC article. Review.
-
ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients.Cancer Cell Int. 2023 Aug 11;23(1):165. doi: 10.1186/s12935-023-03024-3. Cancer Cell Int. 2023. PMID: 37568162 Free PMC article.
-
Differential expression of degradome components in cutaneous squamous cell carcinomas.Mod Pathol. 2014 Jul;27(7):945-57. doi: 10.1038/modpathol.2013.217. Epub 2013 Dec 20. Mod Pathol. 2014. PMID: 24356192 Free PMC article.
References
-
- Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, Docherty AJ, Murphy G (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 473(3): 275–9 - PubMed
-
- Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knauper V, Docherty AJ, Murphy G (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435(1): 39–44 - PubMed
-
- Aung PP, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T, Bosserhoff AK, Yasui W (2006) Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25(17): 2546–2557 - PubMed
-
- Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115(Part 19): 3719–3727 - PubMed
-
- Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12): 915–925 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous